Drug
Post Triheptanoin
Post Triheptanoin: highest development phase Phase 1/2, developed by Ultragenyx Pharmaceutical. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Ultragenyx Pharmaceutical
Trials
| Drug | Phase | Indication |
|---|---|---|
| POST Triheptanoin NCT02679235 | Phase 1/2 | Frontal Lobe Hypometabolism |
Latest
No recent events.
Follow Post Triheptanoin on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.